华北制药 (600812.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.4x

Market Cap

CNY 7.91B

MomentumView details →

1D Return

−6.11%

YTD Return

−15.19%

RSI (14)

42.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.4x

Market Cap

CNY 7.91B

RSI (14)

42.9

MomentumView details →

1D Return

−6.11%

YTD Return

−15.19%

ProfitabilityView details →

Gross Margin

30.96%

Net Margin

1.83%

EBITDA Margin

14.32%

ROE (TTM)

2.90%

ROA (TTM)

0.75%

Asset Turnover

0.41x

GrowthView details →

Revenue YoY

−10.78%

EPS YoY

−3.48%

FCF YoY

+452.17%

Revenue CAGR 3Y

−4.17%

EPS CAGR 3Y

+497.22%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.59x

Current Ratio

0.72x

Quick Ratio

0.51x

Div Yield

0.75%

Div Rate

CNY 0.04

Div Growth 1Y

+16.67%

Financials snapshotView financials →

Revenue (TTM)

8.82B

Net Income (TTM)

161.04M

Op. CF (TTM)

1.17B

Latest newsMore news →

North China Pharmaceutical's subsidiary Shenzhen Huayao South Pharmaceutical received approval from China's National Medical Products Administration on August 24, 2026, to add a 1.8g specification of lysine acetylsalicylate for injection, with both 0.9g and 1.8g specifications passing generic drug consistency evaluation.9d ago

North China Pharmaceutical announced its first-half 2026 results: revenue of 4.220 billion yuan, down 20.01% year-on-year; net profit attributable to shareholders of 63.8459 million yuan, down 48.30% year-on-year.14d ago

Similar companies

太极集团600129.SH SSY Group Limited02005.HK 上海谊众688091.SH 汇宇制药-W688553.SH 鲁抗医药600789.SH Sihuan Pharmaceutical Holdings Group Ltd.00460.HK Find similar companies →

Latest newsMore news →

North China Pharmaceutical's subsidiary Shenzhen Huayao South Pharmaceutical received approval from China's National Medical Products Administration on August 24, 2026, to add a 1.8g specification of lysine acetylsalicylate for injection, with both 0.9g and 1.8g specifications passing generic drug consistency evaluation.9d ago North China Pharmaceutical announced its first-half 2026 results: revenue of 4.220 billion yuan, down 20.01% year-on-year; net profit attributable to shareholders of 63.8459 million yuan, down 48.30% year-on-year.14d ago